Toward PRecisiOn Medicine for the Prediction of Treatment Response in Major Depressive Disorder through Stratification of Combined Clinical and Omics Signatures
Major depressive disorder (MDD) is the most common psychiatric disorder worldwide and represents a leading cause of years lived with disability. A large number of MDD patients do not respond to antidepressant treatment and do not achieve complete symptomatic remission with functional recovery, representing an enormous economic burden for public health systems.
It is extremely important to identify predictive markers at different levels (stratification of clinical features, genetic and gene expression profiles) and to integrate all of this information for its use in real-world settings.
The perspective is to design future clinical trials in which the prediction provided by the integration of clinical and omics signatures is used to drive decision making from both the clinician and patient perspectives.
This project has a unique personalized medicine approach that addresses an important and large medical burden: Treatment resistance in MDD.
An European network
The project brings together experts from different complementary disciplines (clinical psychiatry, omics sciences, bioinformatics, modeling) from different European countries.
PROMPT is committed to promoting gender balance in research teams, ensuring gender balance in decision-making, and integrating the gender dimension into research and innovation.